Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb). This infection may go away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. This study will evaluate the immunogenicity and safety of GSK Biologicals HPV-16/18 vaccine over 12 months, in women up to 55 years of age at study start. Approximately 660 study subjects will receive the HPV vaccine administered intramuscularly according to a 0-1-6 month schedule. The study will be extended to assess long-term safety and immunogenicity of the HPV-16/18 vaccine.


Options:
A: Arm Label: HPV-16/18 Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV 16/18 L1 AS04 | Arm Label: HPV-TETRA A Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 1 | Arm Label: HPV-TETRA B Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 2 | Arm Label: HPV-TETRA C Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 3 | Arm Label: HPV-TETRA D Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 4 | Arm Label: HPV-TETRA E Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 5 | Arm Label: HPV-TETRA F Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 6 | Intervention Type: BIOLOGICAL; Name: HPV 16/18 L1 AS04; Assigned to Arm(s): HPV-16/18 Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 1; Assigned to Arm(s): HPV-TETRA A Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 2; Assigned to Arm(s): HPV-TETRA B Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 3; Assigned to Arm(s): HPV-TETRA C Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 4; Assigned to Arm(s): HPV-TETRA D Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 5; Assigned to Arm(s): HPV-TETRA E Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 6; Assigned to Arm(s): HPV-TETRA F Group
B: Arm Label: Cervarix (15-25 Years) Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: Cervarix (26-45 Years) Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: Cervarix (46-55 Years) Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix (15-25 Years) Group, Cervarix (26-45 Years) Group, Cervarix (46-55 Years) Group
C: Arm Label: qHPV Vaccine in Base Study; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | Arm Label: Placebo in Base Study; Type: PLACEBO_COMPARATOR; Interventions: Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Biological: Comparator: Placebo | Intervention Type: BIOLOGICAL; Name: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine; Assigned to Arm(s): Placebo in Base Study, qHPV Vaccine in Base Study | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): Placebo in Base Study
D: Arm Label: qHPV Vaccine in Base Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: Placebo in Base Study; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: qHPV Vaccine in Extension Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): qHPV Vaccine in Base Study, qHPV Vaccine in Extension Study | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): Placebo in Base Study

Answer: B